A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) (STAR)
2026年6月21日 更新者:Sixth Affiliated Hospital, Sun Yat-sen University
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk locally advanced pMMR/MSS lower rectal adenocarcinoma, aiming to provide high-level evidence supporting a novel treatment paradigm.
調査の概要
状態
募集
研究の種類
介入
入学 (推定)
76
段階
- フェーズ2
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
-
Guangzhou、中国
- 募集
- The Sixth Affiliated Hospital of Sun Yat-sen University
-
コンタクト:
- YiFeng Zou
- 電話番号:13719225862
- メール:zouyif@mail.sysu.edu.cn
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
- Before implementing any procedures related to the study protocol rather than routine clinical care, a signed and dated informed consent form must be obtained from the subject voluntarily, in accordance with regulatory requirements and institutional guidelines.
- Age 18-75 years.
- Histologically or cytologically confirmed pMMR/MSS rectal adenocarcinoma.
- The lower edge of the rectal tumor is located below the peritoneal reflection.
- Locally advanced disease with high-risk factors, meeting at least one of the following: cT4 / cN2 / EMVI+ / MRF+ / positive lateral lymph node.
- No clear evidence of distant metastasis prior to treatment.
- No prior anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
- ECOG performance status 0-1 (Appendix 1).
Peripheral blood counts and liver and renal function within the following ranges (tested within 15 days before treatment initiation):
White blood cell count (WBC) ≥ 3.0 × 10⁹/L or absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;
- Hemoglobin (HGB) ≥ 80 g/L; ③ Platelet count (PLT) ≥ 100 × 10⁹/L; ④ Hepatic transaminases (AST/ALT) < 3.0 × upper limit of normal (ULN); ⑤ Total bilirubin (TBIL) < 1.5 × ULN; ⑥ Creatinine (CREAT) < 1.5 × ULN.
- No history of other concurrent malignancies; not pregnant or lactating; effective contraceptive methods should be used during the study period and for 6 months after the last dose.
Exclusion Criteria:
- Patients with a history of severe drug allergy (including allergy to platinum agents, 5-FU, and 5-HT3 receptor antagonists).
- Patients who have participated in or are currently participating in another clinical trial within 4 weeks prior to enrollment.
- History of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or any other therapy specifically targeting T-cell co-stimulation or checkpoint pathways.
- Severe electrolyte abnormalities.
- Presence of gastrointestinal diseases such as active gastric or duodenal ulcer, ulcerative colitis, or unresected tumor with active bleeding; or other conditions that may cause gastrointestinal bleeding or perforation; or unhealed gastrointestinal perforation after surgical treatment.
- History of arterial thrombosis or deep vein thrombosis within 6 months; evidence of bleeding tendency or hemorrhagic history within 2 months; currently receiving high-dose anticoagulation therapy.
- Pregnant or lactating women, or women of childbearing potential with a positive pregnancy test prior to the first dose; or female participants and their partners who are unwilling to practice strict contraception during the study period.
- Presence of other concurrent or prior active malignancies (except for malignancies that have been curatively treated with no recurrence for more than 3 years, or carcinoma in situ that can be cured by adequate treatment).
- Severe electrocardiogram abnormalities, or active coronary artery disease, severe/unstable angina, newly diagnosed angina or myocardial infarction within 12 months prior to study entry, or congestive heart failure of NYHA Class II or higher.
- Patients with active infection (infection causing fever > 38°C).
- Patients with poorly controlled hypercalcemia, hypertension, or diabetes mellitus.
- Patients with severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.).
- Patients with mental disorders affecting clinical treatment or a history of central nervous system disease.
- Patients with severe complications (intestinal obstruction, renal insufficiency, hepatic insufficiency, cerebrovascular disorders, etc.).
- Presence of any unresolved toxicity of CTCAE Grade 2 or higher resulting from prior therapy (except for anemia, alopecia, and skin pigmentation).
- Any medical condition that is unstable or may affect patient safety and compliance with the study.
- Patients deemed by the investigator to be unsuitable for participation in this clinical trial.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:SCRT-PD1-FOLFOX
|
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
|
|
アクティブコンパレータ:LCRT-FOLFOX
|
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
The neoadjuvant treatment phase includes either SCRT followed by 6 cycles of FOLFOX chemotherapy combined with a PD-1 inhibitor, or LCRT concurrent with 6 cycles of FOLFOX chemotherapy.
Surgery is performed 2-4 weeks after the last cycle of chemotherapy.
If reassessment indicates cCR and N0, options include Total Mesorectal Excision (TME), local excision (LE), or watch and wait (W&W); otherwise, TME is performed.
Postoperative adjuvant chemotherapy follows the CAPOX regimen.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CCR
時間枠:3 years
|
cCR+pCR
|
3 years
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
3-year RFS
時間枠:3 years
|
3 years
|
|
3-year DFS
時間枠:3 years
|
3 years
|
|
3-year OS
時間枠:3 years
|
3 years
|
|
3-year DMFS
時間枠:3 years
|
3 years
|
|
R0 Resection Rate
時間枠:3 years
|
3 years
|
|
MPR Rate
時間枠:3 years
|
3 years
|
|
Treatment-Related Adverse Events / Treatment Toxicity
時間枠:3 years
|
3 years
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年1月1日
一次修了 (推定)
2028年1月1日
研究の完了 (推定)
2028年1月1日
試験登録日
最初に提出
2026年6月21日
QC基準を満たした最初の提出物
2026年6月21日
最初の投稿 (実際)
2026年6月25日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月25日
QC基準を満たした最後の更新が送信されました
2026年6月21日
最終確認日
2026年6月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。